NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC

摘要

The present invention relates to peptides, nucleic acids and cells for use in immunotherapy methods. In particular, the present invention relates to cancer immunotherapy. In addition, the present invention relates to a tumor-associated cytotoxic T cell (CTL) peptide epitope alone or in combination with other tumor-associated peptides acting as an active pharmaceutical ingredient of a vaccine composition that promotes an anti-tumor immune response. The present invention relates to more than 70 novel peptide sequences derived from HLA type I and HLA type II molecules of human tumor cells and variants thereof that can be used in vaccine compositions required to elicit an anti-tumor immune response.